Cancer testis antigen and immunotherapy

References

• YeeCThompsonJAByrdDAdoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and anti-tumor effect of transferred T cellsProc Natl Acad Sci U S A20029925161681617312427970
   PubMed Web of Science ®Google Scholar
• DudleyMEWunderlichJRRobbinsPFCancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytesScience2002298559485085412242449
   PubMed Web of Science ®Google Scholar
• YuJSLiuGYingHYongWHBlackKLWheelerCJVaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant gliomaCancer Res200464144973497915256471
   PubMed Web of Science ®Google Scholar
• KonoKTakahashiASugaiHDendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancerClin Cancer Res20028113394340012429626
   PubMed Web of Science ®Google Scholar
• ComitoMASunQLucasKGImmunotherapy for Epstein-Barr virus-associated tumorsLeuk Lymphoma200445101981198715370241
   PubMed Web of Science ®Google Scholar
• RiddellSRGreenbergPDPrinciples for adoptive T cell therapy of human viral diseasesAnnu Rev Immunol1995135455867612234
   PubMed Web of Science ®Google Scholar
• WalterEAGreenbergPDGilbertMJReconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donorN Engl J Med199533316103810447675046
   PubMed Web of Science ®Google Scholar
• CurranKJPegramHJBrentjensRJChimeric antigen receptors for T cell immunotherapy: current understanding and future directionsJ Gene Med201214640541522262649
   PubMed Web of Science ®Google Scholar
• MorganRADudleyMEWunderlichJRCancer regression in patients after transfer of genetically engineered lymphocytesScience2006314579612612916946036
   PubMed Web of Science ®Google Scholar
• KerkarSPSanchez-PerezLYangSGenetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studiesJ Immunother201134434335221499127
   PubMed Web of Science ®Google Scholar
• ChoiBDCaiMBignerDDMehtaAIKuanCTSampsonJHBispecific antibodies engage T cells for antitumor immunotherapyExpert Opin Biol Ther201111784385321449821
   PubMed Web of Science ®Google Scholar
• BaitschLBaumgaertnerPDevêvreEExhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patientsJ Clin Invest201112162350236021555851
   PubMed Web of Science ®Google Scholar
• NordeWJHoboWvan der VoortRDolstraHCoinhibitory molecules in hematologic malignancies: targets for therapeutic interventionBlood2012120472873622563087
   PubMed Web of Science ®Google Scholar
• GaoJBernatchezCSharmaPRadvanyiLGHwuPAdvances in the development of cancer immunotherapiesTrends Immunol2013342909823031830
   PubMed Web of Science ®Google Scholar
• ZhouQMungerMEHighfillSLProgram death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemiaBlood2010116142484249320570856
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med2012366262455246522658128
   PubMed Web of Science ®Google Scholar
• PeggsKSQuezadaSAChambersCAKormanAJAllisonJPBlockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodiesJ Exp Med200920681717172519581407
   PubMed Web of Science ®Google Scholar
• WeberJReview: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse eventsOncologist200712786487217673617
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• MargolinKErnstoffMSHamidOIpilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialLancet Oncol201213545946522456429
   PubMed Web of Science ®Google Scholar
• WeberJSAminAMinorDSafety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trialMelanoma Res201121653053422051508
   PubMed Web of Science ®Google Scholar
• Di GiacomoAMAsciertoPAPillaLIpilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trialLancet Oncol201213987988622894884
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011364262517252621639810
   PubMed Web of Science ®Google Scholar
• BolhassaniASafaiyanSRafatiSImprovement of different vaccine delivery systems for cancer therapyMol Cancer201110321211062
   PubMed Web of Science ®Google Scholar
• BendandiMGockeCDKobrinCBComplete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphomaNat Med19995101171117710502821
   PubMed Web of Science ®Google Scholar
• GnjaticSSawhneyNBBhardwajNToll-like receptor agonists: are they good adjuvants?Cancer J201016438239120693851
   PubMed Web of Science ®Google Scholar
• PaluckaKBanchereauJCancer immunotherapy via dendritic cellsNat Rev Cancer201212426527722437871
   PubMed Web of Science ®Google Scholar
• SimpsonAJCaballeroOLJungbluthAChenYTOldLJCancer/testis antigens, gametogenesis and cancerNat Rev Cancer20055861562516034368
   PubMed Web of Science ®Google Scholar
• ChenYTRossDSChiuRMultiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancersPLoS One201163e1787621437249
   PubMed Web of Science ®Google Scholar
• CaballeroOLChenYTCancer/testis (CT) antigens: potential targets for immunotherapyCancer Sci2009100112014202119719775
   PubMed Web of Science ®Google Scholar
• RestifoNPDudleyMERosenbergSAAdoptive immunotherapy for cancer: harnessing the T cell responseNat Rev Immunol201212426928122437939
   PubMed Web of Science ®Google Scholar
• ScanlanMJSimpsonAJOldLJThe cancer/testis genes: review, standardization, and commentaryCancer Immun20044114738373
   PubMedGoogle Scholar
• NicholaouTEbertLDavisIDDirections in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1Immunol Cell Biol200684330331716681828
   PubMed Web of Science ®Google Scholar
• ZhangSZhouXYuHYuYExpression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell linesBMC Cancer20101016320423514
   PubMed Web of Science ®Google Scholar
• WangXFCohenWMCastelliFASelective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene familyCancer Immunol Immunother200756680781816988823
   PubMed Web of Science ®Google Scholar
• LuitenRDemotteNTineJvan der BruggenPA MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 moleculesTissue Antigens2000561778110958359
   PubMedGoogle Scholar
• LuitenRvan der BruggenPA MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytesTissue Antigens200055214915210746786
   PubMedGoogle Scholar
• Pastorcic-GrgicMSarcevicBDosenDJureticASpagnoliGCGrgicMPrognostic value of MAGE-A and NY-ESO-1 expression in pharyngeal cancerHead Neck20103291178118420029985
   PubMed Web of Science ®Google Scholar
• YoshidaNAbeHOhkuriTExpression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significanceInt J Oncol20062851089109816596224
   PubMed Web of Science ®Google Scholar
• JungbluthAAAntonescuCRBusamKJMonophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7Int J Cancer200194225225611668506
   PubMed Web of Science ®Google Scholar
• PollackSMJungbluthAAHochBLNY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcomaCancer2012118184564457022359263
   PubMed Web of Science ®Google Scholar
• WölflMJungbluthAAGarridoFExpression of MHC class I, MHC class II, and cancer germline antigens in neuroblastomaCancer Immunol Immunother200554440040615449039
   PubMed Web of Science ®Google Scholar
• RodolfoMLukschRStockertEAntigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigenCancer Res200363206948695514583496
   PubMed Web of Science ®Google Scholar
• BarrowCBrowningJMacGregorDTumor antigen expression in melanoma varies according to antigen and stageClin Cancer Res2006123 Pt 176477116467087
   PubMed Web of Science ®Google Scholar
• DhodapkarMVOsmanKTeruya-FeldsteinJExpression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of diseaseCancer Immun20033912875607
   PubMedGoogle Scholar
• SuyamaTShiraishiTZengYExpression of cancer/testis antigens in prostate cancer is associated with disease progressionProstate201070161778178720583133
   PubMed Web of Science ®Google Scholar
• ChauxPLuitenRDemotteNIdentification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1J Immunol199916352928293610453041
   PubMed Web of Science ®Google Scholar
• Chianese-BullockKAPressleyJGarbeeCMAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanomaJ Immunol200517453080308615728523
   PubMed Web of Science ®Google Scholar
• CarrascoJVan PelANeynsBVaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cellsJ Immunol200818053585359318292586
   PubMed Web of Science ®Google Scholar
• ThurnerBHaendleIRöderCVaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanomaJ Exp Med1999190111669167810587357
   PubMed Web of Science ®Google Scholar
• ConnerotteTVan PelAGodelaineDFunctions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalitiesCancer Res200868103931394018483279
   PubMed Web of Science ®Google Scholar
• GoodyearOAgathanggelouANovitzky-BassoIInduction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasiaBlood2010116111908191820530795
   PubMed Web of Science ®Google Scholar
• NishikawaHMaedaYIshidaTCancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphomaBlood2012119133097310422323448
   PubMed Web of Science ®Google Scholar
• JägerENagataYGnjaticSMonitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responsesProc Natl Acad Sci U S A20009794760476510781081
   PubMed Web of Science ®Google Scholar
• JägerEGnjaticSNagataYInduction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancersProc Natl Acad Sci U S A20009722121981220311027314
   PubMed Web of Science ®Google Scholar
• MacKensenAHerbstBChenJLPhase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cellsInt J Cancer200086338539210760827
   PubMed Web of Science ®Google Scholar
• ShackletonMDavisIDHopkinsWThe impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligandCancer Immun20044915384929
   PubMedGoogle Scholar
• ChenQJacksonHShackletonMCharacterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccinationCancer Immun20055515755075
   PubMedGoogle Scholar
• BenderAKarbachJNeumannALUD 00-009: phase 1study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancerCancer Immun200771617944437
   PubMedGoogle Scholar
• DavisIDChenWJacksonHRecombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humansProc Natl Acad Sci U S A200410129106971070215252201
   PubMed Web of Science ®Google Scholar
• NicholaouTChenWDavisIDImmunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™Cancer Immunol Immunother201160111625163721698545
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011364262517252621639810
   PubMed Web of Science ®Google Scholar
• RosenblattJGlotzbeckerBMillsHPD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccineJ Immunother201134540941821577144
   PubMed Web of Science ®Google Scholar
• GulleyJLArlenPMBastianACombining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancerClin Cancer Res20051193353336215867235
   PubMed Web of Science ®Google Scholar
• ArlenPMGulleyJLParkerCA randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancerClin Cancer Res20061241260126916489082
   PubMed Web of Science ®Google Scholar
• LaheruDLutzEBurkeJAllogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activationClin Cancer Res20081451455146318316569
   PubMed Web of Science ®Google Scholar
• FarsaciBHigginsJPHodgeJWConsequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapyInt J Cancer201213081948195921633954
   PubMed Web of Science ®Google Scholar
• StaggJLoiSDivisekeraUAnti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapyProc Natl Acad Sci U S A2011108177142714721482773
   PubMed Web of Science ®Google Scholar
• VannemanMDranoffGCombining immunotherapy and targeted therapies in cancer treatmentNat Rev Cancer201212423725122437869
   PubMed Web of Science ®Google Scholar
• RechAJVonderheideRHClinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cellsAnn N Y Acad Sci200911749910619769742
   PubMed Web of Science ®Google Scholar
• JacobsJFPuntCJLesterhuisWJDendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patientsClin Cancer Res201016205067507820736326
   PubMed Web of Science ®Google Scholar
• ZhaoJCaoYLeiZYangZZhangBHuangBSelective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levelsCancer Res201070124850485820501849
   PubMed Web of Science ®Google Scholar
• van der MostRGCurrieAJMahendranSTumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapyCancer Immunol Immunother20095881219122819052741
   PubMed Web of Science ®Google Scholar
• De SmetCLurquinCLethéBDNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoterMol Cell Biol199919117327733510523621
   PubMed Web of Science ®Google Scholar
• YeQShenYWangXHypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancerTissue Antigens2010751303919883394
   PubMedGoogle Scholar
• MarksPRifkindRARichonVMBreslowRMillerTKellyWKHistone deacetylases and cancer: causes and therapiesNat Rev Cancer20011319420211902574
   PubMed Web of Science ®Google Scholar
• YangHHoshinoKSanchez-GonzalezBKantarjianHGarcia-ManeroGAntileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acidLeuk Res200529773974815927669
   PubMed Web of Science ®Google Scholar
• Garcia-ManeroGGoreSDFuture directions for the use of hypomethylating agentsSemin Hematol2005423 Suppl 2S50S5916015506
   PubMed Web of Science ®Google Scholar
• IssaJPGharibyanVCortesJPhase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylateJ Clin Oncol200523173948395615883410
   PubMed Web of Science ®Google Scholar
• AdairSJHoganKTTreatment of ovarian cancer cell lines with 5-aza-2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded moleculesCancer Immunol Immunother200958458960118791715
   PubMed Web of Science ®Google Scholar
• SchrumpDSFischetteMRNguyenDMPhase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleuraClin Cancer Res200612195777578517020984
   PubMed Web of Science ®Google Scholar
• WeberJSalgallerMSamidDExpression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidineCancer Res1994547176617717511051
   PubMed Web of Science ®Google Scholar
• AlmstedtMBlagitko-DorfsNDuque-AfonsoJThe DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cellsLeuk Res201034789990520381863
   PubMed Web of Science ®Google Scholar
• SerranoATanzarellaSLionelloIRexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatmentInt J Cancer200194224325111668505
   PubMed Web of Science ®Google Scholar
• SigalottiLAltomonteMColizziF5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?Blood2003101114644464612756166
   PubMed Web of Science ®Google Scholar
• OiSNatsumeAItoMSynergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2′-deoxycytidine in glioma cellsJ Neurooncol2009921152219030781
   PubMed Web of Science ®Google Scholar
• NatsumeAWakabayashiTTsujimuraKThe DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human gliomaInt J Cancer2008122112542255318240144
   PubMed Web of Science ®Google Scholar
• BaoLDunhamKLucasKMAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killingCancer Immunol Immunother20116091299130721626030
   PubMed Web of Science ®Google Scholar
• KrishnadasDKShapiroTLucasKComplete remission following decitabine/dendritic cell vaccine for relapsed neuroblastomaPediatrics20131311e336e34123266925
   PubMed Web of Science ®Google Scholar
• RobbinsPFMorganRAFeldmanSATumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1J Clin Oncol2011297917929021282551
   PubMed Web of Science ®Google Scholar